Article thumbnail

The schizophrenia prodrome: promise for prevention

By Barbara Cornblatt

Abstract

Converging theoretical, psychopharmacological, neurodevelopmental advances have led to increasing interest in preventive intervention in schizophrenia. In particular, evidence suggests that early treatment is associated with a better prognosis. Furthermore, based on the reported reduction in severe side effects, the new novel antipsychotics potentially provide the tools for early intervention. Nevertheless, initiation of intervention during the prodrome has become controversial because of such unresolved issues as: (i) how to accurately identify susceptible individuals who are in true need of preventive intervention; (ii) at what developmental point in the prodrome medication should be initiated; (iii) how long medication should be continued; and (iv) what medication is optimal for each phase of the prodrome. By adopting a naturalistic, prospective research strategy, the Recognition and Prevention (RAP) program now underway in New York has been designed to address these and other important questions involved in prodromal research and treatment

Topics: Basic Research
Publisher: Les Laboratoires Servier
OAI identifier: oai:pubmedcentral.nih.gov:3181647
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1984). Affective psychopathology in Huntington's disease: the Johns Hopkins hypothesis and German psychiatry. Psychol Med.
  2. an der Heiden W. Epidemiology of schizophrenia.
  3. Are self-perceivable neuropsychological deficits in patients with neuroses or personality disorder diagnoses indicative of later schizophrenia?
  4. (1997). Attention and clinical symptoms in schizophrenia. Psychiatr Q.
  5. (1997). Backward masking performance in unaffected siblings of schizophrenic patients. Evidence for a vulnerability indicator. Arch Gen Psychiatry.
  6. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents.
  7. (1946). Child developmental risk factors for adult schizophrenia in the British
  8. (1999). Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol.
  9. (1998). Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatry Res.
  10. Department of Veterans Affairs Cooperative Studies Program genetic linkage study of schizophrenia: ascertainment methods and sample description.
  11. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry.
  12. (1996). Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci.
  13. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
  14. (1998). Droperidol in the interim management of severe mania: case reports and literature review. Clin Neuropharmacol.
  15. (1992). Duration of psychosis and outcome in first-episode schizophrenia.
  16. (1999). Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry.
  17. (1996). Early detection and intervention in schizophrenia. Schizophr Bull.
  18. (1999). Early recognition in schizophrenia: the prodromal stages. J Pract Psychiatr Behav Health.
  19. Early subjective experience in schizophrenic episodes.
  20. (1990). Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull.
  21. Epidemiology of early-onset schizophrenia.
  22. (1996). EPPIC: an evolving system of early detection and optimal management. Schizophr Bull.
  23. Establishing the onset of psychotic illness.
  24. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care.
  25. (1994). Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull.
  26. (1990). Increased morbid risk for schizophrenia-related disorder in relatives of schizotypal personality disorder patients. Arch Gen Psychiatry.
  27. (1996). Initial prodrome in psychosis: descriptive and qualitative aspects.
  28. (1992). IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res.
  29. (1997). Long-term morbidity associated withBasic research delayed treatment of first admission schizophrenia patients: a re-analysis of the Camarillo State Hospital data. Psychol Med.
  30. Longitudinal studies of schizophrenic patients.
  31. Monitoring and care of young people at incipient risk of psychosis.
  32. (1999). negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand.
  33. Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness.
  34. (1993). Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull.
  35. (1991). Neuroleptics and the natural course of schizophrenia. Schizophr Bull.
  36. (1998). Prediction of psychosis. A step towards indicated prevention of schizophrenia.
  37. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry.
  38. (2000). Rapid versus delayed readmission in first-admission psychosis: quality indicators for managed care? Ann Clin Psychiatry.
  39. (1996). Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull.
  40. (1999). Risperidone versus haloperidol on secondary memory: can newer medication aid learning? Schizophr Bull.
  41. Schizophrenia: life-time course.
  42. (1995). Schizotypal symptoms and signs in the Roscommon Family Study. Their factor structure and familial relationship with psychotic and affective disorders. Arch Gen Psychiatry.
  43. (1994). Single indicator of risk for schizophrenia: probable fact or likely myth? Schizophr Bull.
  44. (1999). Symptom assessment in schizophrenic prodromal states. Psychiatr Q.
  45. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull.
  46. (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull.
  47. The meaning of basic symptoms for the development of schizophrenic psychoses.
  48. (1995). The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand.
  49. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull.
  50. (1998). The profiles of clinical deterioration in schizophrenia.
  51. (1997). The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies. Psychol Med.
  52. (1993). The schizophrenia high-risk project in Copenhagen: three decades of progress. Acta Psychiatr Scand.
  53. (1998). Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
  54. Untreated initial psychosis: its relation to quality of life and symptom remission in firstepisode schizophrenia.
  55. (1999). What should be used for generating predictive models? Schizophr Res.